Chemotherapy

Most U.S. cancer centers reported experiencing a shortage of at least one type of oncology drug, according to the results of a National Comprehensive Cancer Network survey on chemotherapy shortages.

A small study showed no impact from troponin-guided carvedilol and candesartan intervention to preserve cardiac function among seemingly high-risk patients undergoing chemotherapy.

Datopotamab deruxtecan significantly improved PFS compared with chemotherapy in patients with previously treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer, according to the agent’s manufacturers.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about combining different therapeutic modalities for advanced endometrial cancer.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about treatment options for advanced recurrent endometrial cancer.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about recent advancements in endometrial cancer.

Osimertinib plus chemotherapy conferred significantly greater improvement in PFS compared with osimertinib alone in patients with EGFR-mutated advanced non-small cell lung cancer, according to study results.

The addition of benmelstobart and anlotinib to chemotherapy significantly improved median PFS and OS compared with chemotherapy alone among patients with extensive-stage small cell lung cancer, according to study results.

Intensive consolidation chemotherapy prior to allogeneic hematopoietic stem cell transplant provided no greater benefit than nonintensive consolidation for older adults with acute myeloid leukemia, according to study results.

Ponatinib improved outcomes compared with imatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to study results presented at Society of Hematologic Oncology Annual Meeting.